Our top pick for
This article contains links to products or services from one or more of our advertisers or partners. We may receive a commission when you click or make a purchase using our site. Learn more about how we make money.
Meridian Bioscience, Inc is a diagnostics & research business based in the US. Meridian Bioscience shares (VIVO) are listed on the NASDAQ and all prices are listed in US Dollars.
|Latest market close||USD$18.05|
|52-week range||USD$5.51 - USD$26.58|
|50-day moving average||USD$18.1983|
|200-day moving average||USD$18.4995|
|Wall St. target price||USD$25.58|
|Dividend yield||N/A (1.27%)|
|Earnings per share (TTM)||USD$1.07|
The value of any investment can go up or down depending on news, trends and market conditions. We are not investment advisers, so do your own due diligence to understand the risks before you invest.
The technical analysis gauge below displays real-time ratings for the timeframes you select. This is not a recommendation, however. It represents a technical analysis based on the most popular technical indicators: Moving Averages, Oscillators and Pivots. Finder might not concur and takes no responsibility.
This chart is not advice or a guarantee of success. Rather, it gauges the real-time recommendations of three popular technical indicators: moving averages, oscillators and pivots. Finder is not responsible for how your stock performs.
|1 week (2020-11-25)||1.63%|
|1 month (2020-11-06)||-3.37%|
|3 months (2020-09-04)||31.75%|
|6 months (2020-06-05)||14.28%|
|1 year (2019-12-05)||98.57%|
|2 years (2018-12-04)||-3.53%|
|3 years (2017-12-05)||21.96%|
|5 years (2015-12-04)||-7.91%|
Valuing Meridian Bioscience stock is incredibly difficult, and any metric has to be viewed as part of a bigger picture of Meridian Bioscience's overall performance. However, analysts commonly use some key metrics to help gauge the value of a stock.
Meridian Bioscience's current share price divided by its per-share earnings (EPS) over a 12-month period gives a "trailing price/earnings ratio" of roughly 18x. In other words, Meridian Bioscience shares trade at around 18x recent earnings.
That's relatively low compared to, say, the trailing 12-month P/E ratio for the NASDAQ 100 at the end of 2019 (27.29). The low P/E ratio could mean that investors are pessimistic about the outlook for the shares or simply that they're under-valued.
Meridian Bioscience's "price/earnings-to-growth ratio" can be calculated by dividing its P/E ratio by its growth – to give 1.33. A low ratio can be interpreted as meaning the shares offer better value, while a higher ratio can be interpreted as meaning the shares offer worse value.
The PEG ratio provides a broader view than just the P/E ratio, as it gives more insight into Meridian Bioscience's future profitability. By accounting for growth, it could also help you if you're comparing the share prices of multiple high-growth companies.
Meridian Bioscience's EBITDA (earnings before interest, taxes, depreciation and amortisation) is USD$74.2 million.
The EBITDA is a measure of a Meridian Bioscience's overall financial performance and is widely used to measure a its profitability.
|Revenue TTM||USD$253.7 million|
|Operating margin TTM||24.32%|
|Gross profit TTM||USD$156.2 million|
|Return on assets TTM||9.64%|
|Return on equity TTM||21.77%|
|Market capitalisation||USD$816.7 million|
TTM: trailing 12 months
There are currently 3.4 million Meridian Bioscience shares held short by investors – that's known as Meridian Bioscience's "short interest". This figure is 0.5% up from 3.4 million last month.
There are a few different ways that this level of interest in shorting Meridian Bioscience shares can be evaluated.
Meridian Bioscience's "short interest ratio" (SIR) is the quantity of Meridian Bioscience shares currently shorted divided by the average quantity of Meridian Bioscience shares traded daily (recently around 559261.95121951). Meridian Bioscience's SIR currently stands at 6.15. In other words for every 100,000 Meridian Bioscience shares traded daily on the market, roughly 6150 shares are currently held short.
However Meridian Bioscience's short interest can also be evaluated against the total number of Meridian Bioscience shares, or, against the total number of tradable Meridian Bioscience shares (the shares that aren't held by "insiders" or major long-term shareholders – also known as the "float"). In this case Meridian Bioscience's short interest could be expressed as 0.08% of the outstanding shares (for every 100,000 Meridian Bioscience shares in existence, roughly 80 shares are currently held short) or 0.1073% of the tradable shares (for every 100,000 tradable Meridian Bioscience shares, roughly 107 shares are currently held short).
A SIR below 10% would generally be considered to indicate a fairly optimistic outlook for the share price, with fewer people currently willing to bet against Meridian Bioscience.
Find out more about how you can short Meridian Bioscience stock.
We're not expecting Meridian Bioscience to pay a dividend over the next 12 months.
Meridian Bioscience's shares were split on a 3:2 basis on 14 May 2007. So if you had owned 2 shares the day before before the split, the next day you'd have owned 3 shares. This wouldn't directly have changed the overall worth of your Meridian Bioscience shares – just the quantity. However, indirectly, the new 33.3% lower share price could have impacted the market appetite for Meridian Bioscience shares which in turn could have impacted Meridian Bioscience's share price.
Over the last 12 months, Meridian Bioscience's shares have ranged in value from as little as $5.51 up to $26.58. A popular way to gauge a stock's volatility is its "beta".
Beta is a measure of a share's volatility in relation to the market. The market (NASDAQ average) beta is 1, while Meridian Bioscience's is 0.5502. This would suggest that Meridian Bioscience's shares are less volatile than average (for this exchange).
Meridian Bioscience, Inc., a life science company, develops, manufactures, distributes, and sells diagnostic test kits primarily for gastrointestinal and respiratory infectious diseases, and elevated blood lead levels worldwide. The company operates through Diagnostics and Life Science segments. The Diagnostics segment offers testing platforms, including real-time PCR amplification under the Revogene brand; isothermal DNA amplification under the Alethia brand; lateral flow immunoassay using fluorescent chemistry under the Curian brand; rapid immunoassay under the ImmunoCard and ImmunoCard STAT! brands; enzyme-linked immunoassays under the PREMIER brand; anodic stripping voltammetry under the LeadCare and PediaStat brands; and urea breath testing for H. pylori under the BreathID brand. This segment also offers gastrointestinal assays, including tests for C. difficile, H. pylori, and certain foodborne pathogens; respiratory illness assays, such as tests Group A strep, mycoplasma pneumonia, influenza, and pertussis; and blood chemistry assays for testing elevated levels of lead in blood. It sells products through direct sales force and independent distributors to acute care hospitals, reference laboratories, outpatient clinics, and physician office laboratories. The Life Science segment offers bulk antigens, antibodies, PCR/qPCR reagents, nucleotides, and bioresearch reagents used by in vitro diagnostic manufacturers, as well as researchers in immunological and molecular tests for human, animal, plant, and environmental applications. The company has a strategic collaboration with DiaSorin Inc. to sell H. pylori tests. Meridian Bioscience, Inc. was incorporated in 1976 and is headquartered in Cincinnati, Ohio.
Steps to owning and managing HTZ, with 24-hour and historical pricing before you buy.
Steps to owning and managing HELE, with 24-hour and historical pricing before you buy.
Steps to owning and managing HE, with 24-hour and historical pricing before you buy.
Steps to owning and managing GKOS, with 24-hour and historical pricing before you buy.
Steps to owning and managing EYEN, with 24-hour and historical pricing before you buy.
Steps to owning and managing EXAS, with 24-hour and historical pricing before you buy.
Steps to owning and managing EVFM, with 24-hour and historical pricing before you buy.
Steps to owning and managing MRAM, with 24-hour and historical pricing before you buy.
Steps to owning and managing EQNR, with 24-hour and historical pricing before you buy.
Steps to owning and managing SOLO, with 24-hour and historical pricing before you buy.
finder.com is an independent comparison platform and information service that aims to provide you with the tools you need to make better decisions. While we are independent, the offers that appear on this site are from companies from which finder.com receives compensation. We may receive compensation from our partners for placement of their products or services. We may also receive compensation if you click on certain links posted on our site. While compensation arrangements may affect the order, position or placement of product information, it doesn't influence our assessment of those products. Please don't interpret the order in which products appear on our Site as any endorsement or recommendation from us. finder.com compares a wide range of products, providers and services but we don't provide information on all available products, providers or services. Please appreciate that there may be other options available to you than the products, providers or services covered by our service.